An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.
Ontology highlight
ABSTRACT: Fusion proteins combining oligomeric assemblies of a genetically obtained single-chain (sc) variant of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with antibodies directed against tumor-associated antigens represent a promising strategy to overcome the limited therapeutic activity of conventional soluble TRAIL. To further improve the scTRAIL module in order to obtain a robust, thermostable molecule of high activity, we performed a comprehensive analysis of the minimal TNF homology domain (THD) and optimized linkers between the 3 TRAIL subunits constituting a scTRAIL. Through a stepwise mutagenesis of the N- and C-terminal region and the joining linker sequences, we generated bioactive scTRAIL molecules comprising a covalent linkage of the C-terminal Val280 and the N-ter
SUBMITTER: Siegemund M
PROVIDER: S-EPMC4968136 | biostudies-literature | 2016 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA